title: Outcomes of total pelvic exenteration for colorectal cancer.
abstract: OBJECTIVE
  Pelvic recurrence occurs in 4-33% of patients who have undergone a curative resection of primary rectal cancer and is thus a serious problem. However, the best treatment for primary rectal cancer remains unclear. In the present study was assessed the outcomes of total pelvic exenteration for colorectal cancer retrospectively.
  
  
  METHODS
  In the present study was investigated the medical charts of 25 patients who underwent total pelvic exenteration for primary colorectal cancer (n = 12) or postoperative local recurrence of colorectal cancer (n = 13) at the Department of Surgery (Division of Digestive Surgery) of the Kyoto Prefectural University of Medicine between the years 1997-2005.
  
  
  RESULTS
  The mean disease-free time interval between the first operation for primary colorectal cancer and total pelvic exenteration for the recurrence was 919 days (range, 203-3460 days). Total pelvic exenteration required a mean operation time of 940 minutes (range, 540-1395 minutes). The mean carcinoembryonic antigen (CEA) value was 25.5 ng/ml (range, 1-171.8 ng/ml). Five-year survival was achieved in 9 patients (36%) and inhospital death occurred in 3 patients (12%). The patients with curative resection survived significantly longer than the patients with non-curative resection.
  
  
  CONCLUSIONS
  When curative resection is achieved, total pelvic exenteration for colorectal cancer can result in long-term survival.
authors.affiliation: Department of Surgery and Regenerative Medicine, Division of Surgery and Physiology of the Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi, Kamigyo-ku, Kyoto, Japan.
authors.forename: Minoru
authors.initials: M
authors.lastname: Nishio
authors.forename: Chohei
authors.initials: C
authors.lastname: Sakakura
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nagata
authors.forename: Atsushi
authors.initials: A
authors.lastname: Miyashita
authors.forename: Takuo
authors.initials: T
authors.lastname: Hamada
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubota
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Akio
authors.initials: A
authors.lastname: Kimura
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Syoujirou
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Toshiya
authors.initials: T
authors.lastname: Ochiai
authors.forename: Yukihito
authors.initials: Y
authors.lastname: Kokuba
authors.forename: Hiroki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Teruhisa
authors.initials: T
authors.lastname: Sonoyama
authors.forename: Akeo
authors.initials: A
authors.lastname: Hagiwara
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D000328:Adult; D000368:Aged; D015179:Colorectal Neoplasms / Q000401:mortality / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D010385:Pelvic Exenteration; D015996:Survival Rate; D016896:Treatment Outcome